Drugs / 68Ga-AAZTA-NI-093
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06612580 | Sep 2024 → Aug 2025 overdue | prostate adenocarcinoma | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-AAZTA-NI-093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06612580 ↗ |
| Route | Intravenous | “Intravenous injection” NCT06612580 ↗ |